The clinical course of a child with CINCA/IMOMID syndrome improved during and after treatment with thalidomide

Scandinavian Journal of Rheumatology

Volumn 34, Issue 3, 2005, Pages 246-249

  Kallinich, Tilmann ^a,c   Hoffman, H M ^b   Roth, J ^a   Keitzer, R ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE;

ADOLESCENT; ARTHROPATHY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CIAS1 GENE; CINCA SYNDROME; CLINICAL FEATURE; DISEASE COURSE; EYE DISEASE; FEMALE; GENE; GENE MUTATION; HUMAN; NEUROLOGIC DISEASE; NOMID SYNDROME; OSSIFICATION; PATHOGENESIS; PRIORITY JOURNAL; RARE DISEASE; RASH;

ADOLESCENT; AGE OF ONSET; ARTHRITIS; CALCINOSIS; CARRIER PROTEINS; CHRONIC DISEASE; EXANTHEMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MUTATION; SYNDROME; THALIDOMIDE; TIBIA;

EID: 22144447157     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740410010236     Document Type: Article

References (15)

1. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory.
2. Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheum Suppl 1987;66:57-68.
3. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8.
4. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203.
5. Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated auto-inflammatory disorders (CINCA/NOMID, MWS, FCU). Blood 2004;103:2809-15.
6. Richards N, Schaner P, Diaz A, Stuckey J, Shelden E, Wadhwa A, Gumucio DL. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001;276:39320-9.
7. Wang L, Manji GA, Grenier JM, Al-Garawi A, Merriam S, Lora JM, et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem 2002;277:29874-80.
8. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20: 319-25.
9. Prieur AM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001;19:103-6.
10. Rosen-Wolff A, Quietzsch J, Schroder H, Lehmann R, Gahr M, Roesler J. Two German CINCA (NOMID) patients with different clinical severity and response to anti-inflammatory treatment. Eur J Haematol 2003;71:215-19.
11. De Cunto CL, Liberatore DI, San Roman JL, Goldberg JC, Morandi AA, Feldman G. Infantile-onset multisystem inflammatory disease: a differential diagnosis of systemic juvenile rheumatoid arthritis. J Pediatr 1997;130:551-6.
12. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 2003;32:312-14.
13. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12.
14. Dredge K, Marriott JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002;22:425-37.
15. Ossandon A, Cassara EA, Priori R, Valesini G. Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol 2002;20:709-18.